Enhanced Post-Transplant Survival Linked to Immunotherapy in Liver Cancer Patients
A recent study reveals that an immunotherapy-based strategy before liver transplantation significantly improves survival rates for hepatocellular carcinoma patients.
Patients receiving immunotherapy before liver transplantation showed a median overall survival of 4.6 years compared to 2.5 years for those who did not.
The study involved 416 patients, with notable improvements in recurrence-free survival and overall survival rates.
Despite better oncological outcomes, the immunotherapy approach was associated with a higher incidence of acute rejection post-transplant.
A new study has found that employing an immune checkpoint inhibitor-based multimodal downstaging strategy prior to liver transplantation can lead to significantly improved survival rates for patients suffering from hepatocellular carcinoma (HCC) that initially exceeds the Milan criteria. Conducted across eight high-volume transplant centers in China, the research highlights the potential benefits of this approach, which combines immunotherapy with locoregional and targeted therapies.
The study evaluated patients who underwent liver transplantation between January 2019 and December 2024, specifically those whose HCC was beyond the Milan criteria, which typically defines eligibility based on tumor size and number. The researchers utilized propensity score matching to ensure a balanced comparison between those who received the immunotherapy strategy and those who did not, resulting in a matched cohort of 416 transplant recipients.
Key findings from the study revealed that the median overall survival for patients treated with the immunotherapy-based strategy was 4.6 years, a substantial increase compared to 2.5 years for those receiving standard treatment. Additionally, the median recurrence-free survival was reported at 1.5 years for the immunotherapy group versus 0.9 years for the comparator group. Multivariable analyses confirmed that the immunotherapy strategy was linked to improved survival outcomes and a reduced risk of recurrence post-transplant.
However, the study also noted a concerning trend: patients who received the immunotherapy approach experienced a higher rate of acute rejection within the first 90 days following transplantation, with rates of 16.3% compared to 8.2% in the non-immunotherapy group. This highlights a critical aspect of patient management that needs to be addressed as the medical community considers the integration of immunotherapy into liver transplantation protocols.
Looking forward, the authors of the study emphasize the necessity for prospective multicenter studies and randomized clinical trials to further validate these findings. They aim to refine the selection criteria for transplant candidates and develop strategies to manage the increased rejection risk associated with immunotherapy. The research was led by Dr. Qi Ling and Dr. Guangming Li, with support from various scientific grants, and no conflicts of interest were reported by the authors.
